Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, placebo-controlled, parallel group study to demonstrate the subjective treatment effects of ramelteon on sleep using a post sleep questionnaire - Interactive Voice Response System (PSQ-IVRS) in an 'at-home setting' in an adult population with chronic insomnia

Next Previous
X
Search
Trial Profile

A randomized, double blind, placebo-controlled, parallel group study to demonstrate the subjective treatment effects of ramelteon on sleep using a post sleep questionnaire - Interactive Voice Response System (PSQ-IVRS) in an 'at-home setting' in an adult population with chronic insomnia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center

    • Most Recent Events

    • 25 Jun 2008 The expected completion date for this trial is now 1 Nov 2007.
    • 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top